Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer-Reference-Cited by-同舟云学术

Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer

Published:2016-06-28 Issue:7 Volume:107 Page:1006-1012
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Sasaki Yusuke¹,Akasu Takayuki²,Saito Norio³,Kojima Hiroshi⁴,Matsuda Keiji⁵,Nakamori Shoji⁶,Komori Koji⁷,Amagai Kenji⁸,Yamaguchi Tatsuro⁹,Ohue Masayuki¹⁰,Nagashima Kengo¹¹,Yamada Yasuhide¹

Affiliation:

1. Gastrointestinal Medical Oncology Division National Cancer Center Hospital Tokyo Japan

2. Department of Surgery Imperial Household Agency Hospital TokyoJapan

3. Division of Colorectal Surgery National Cancer Center Hospital East KashiwaJapan

4. Division of Gastrointestinal Surgery Prefectural Aichi Hospital OkazakiJapan

5. Department of Surgery Teikyo University School of Medicine TokyoJapan

6. Department of Surgery National Hospital Organization Osaka National Hospital OsakaJapan

7. Department of Gastroenterological Surgery Aichi Cancer Center Hospital NagoyaJapan

8. Division of Gastroenterology and Gastrointestinal Oncology Ibaraki Prefectural Central Hospital and Cancer Center KasamaJapan

9. Department of Surgery Infectious Diseases Center Komagome Hospital TokyoJapan

10. Department of Surgery Osaka Medical Center for Cancer and Cardiovascular Diseases OsakaJapan

11. Department of Global Clinical Research Chiba University Graduate School of Medicine Chiba Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12950

Reference30 articles.

1. Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

2. Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

3. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC)

5. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: Final results of JCOG0205

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real impact of oxaliplatin in adjuvant chemotherapy for patients with stage III colon cancer based on the Multi-Institutional Registry of Large Bowel Cancer in Japan;Global Health & Medicine;2022-10-31

2. PD-1 Blockade in Mismatch Repair–Deficient Rectal Cancer;New England Journal of Medicine;2022-09-01

3. Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape;The Journal of Pathology;2022-04

4. Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis;Scientific Reports;2022-01-20

5. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell;World Journal of Surgical Oncology;2020-08-07